SITE013-0226

SITE013 (USA) › SITE013-0226

SITE013-0226

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2026-06-01

enrolled

AEs

4

Serious

1

Dropout signal

–

Adverse events

4

Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2023-02-22 (study day 84); relationship: not assessed

mild assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 48); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 28); relationship: NOT RELATED

moderate assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 3); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.